Sage Journals: Discover world-class research

Abstract

The mesencephalic locomotor region (MLR) controls locomotion in vertebrates. In humans with Parkinson disease, locomotor deficits are increasingly associated with decreased activity in the MLR. This brainstem region, commonly considered to include the cuneiform and pedunculopontine nuclei, has been explored as a target for deep brain stimulation to improve locomotor function, but the results are variable, from modest to promising. However, the MLR is a heterogeneous structure, and identification of the best cell type to target is only beginning. Here, I review the studies that uncovered the role of genetically defined MLR cell types, and I highlight the cells whose activation improves locomotor function in animal models of Parkinson disease. The promising cell types to activate comprise some glutamatergic neurons in the cuneiform and caudal pedunculopontine nuclei, as well as some cholinergic neurons of the pedunculopontine nucleus. Activation of MLR GABAergic neurons should be avoided, since they stop locomotion or evoke bouts flanked with numerous stops. MLR is also considered a potential target in spinal cord injury, supranuclear palsy, primary progressive freezing of gait, or stroke. Better targeting of the MLR cell types should be achieved through optimized deep brain stimulation protocols, pharmacotherapy, or the development of optogenetics for human use.

Keywords

locomotion gait freezing mesencephalic locomotor region deep brain stimulation cuneiform nucleus pedunculopontine nucleus Parkinson disease

In vertebrates, a key brain region involved in the control of locomotion is the mesencephalic locomotor region (MLR; Shik and others 1966). Located at the border between the mesencephalon and rhombencephalon, it controls locomotor initiation, locomotor speed, gait transitions, and even locomotor arrests (Arber and Costa 2022; for recent review, Ferreira-Pinto and others 2018; Grillner and El Manira 2020; Leiras and others 2022; Noga and Whelan 2022). The MLR is strongly conserved in vertebrates (Figure 1A–E). Electrical stimulation of the MLR controls locomotor output in lamprey (Sirota and others 2000; Figure 1F), zebrafish (Carbo-Tano and others 2022; Figure 1G), stingray (Bernau and others 1991), salamander (Cabelguen and others 2003; Figure 1H), rat (Bachmann and others 2013; Garcia-Rill and others 1987; Hofer and others 2022; Figure 1I), mouse (Roseberry and others 2016), rabbit (Musienko and others 2008), goose (Steeves and others 1987), pig (Chang, Santamaria, and others 2021), cat (Opris and others 2019; Shik and others 1966), and monkey (Eidelberg and others 1981; Gay and others 2020; Goetz and others 2016). It does so by providing direct glutamatergic input to reticulospinal neurons in the reticular formation—as demonstrated in lamprey (Brocard and Dubuc 2003; Le Ray and others 2003), zebrafish (Carbo-Tano and others 2022), salamander (Ryczko, Auclair, and others 2016), and mouse (Bretzner and Brownstone 2013; Capelli and others 2017)—which send direct input to interneurons of the central pattern generator for locomotion, as shown in lamprey (Buchanan and Grillner 1987; for review, Grillner and El Manira 2020; Leiras and others 2022; Figure 1A). In humans, the MLR is activated when people are asked to imagine that they are walking (Karachi and others 2010), and locomotor deficits appear if the MLR is damaged (Demain and others 2014; Kuo and others 2008; Masdeu and others 1994).

Figure 1.

Brainstem locomotor circuits are evolutionary conserved. (A) Left: vertebrate evolution from lamprey to mammals. Right: the three basic layers of the locomotor circuitry conserved in vertebrates. (B–E) Brains of lamprey (adapted from Ryczko and others 2020), zebrafish (adapted from Carbo-Tano and others 2022), salamander (Ryczko, Auclair, and others 2016), and rodent (adapted from Ryczko, Cone, and others 2016). In mammals, many reticulospinal neurons are distributed in the pontine and medullary reticular formations (RFs). Possible homologs of the mammalian pontine RFs are highlighted in lamprey (anterior rhombencephalic reticular nucleus [ARRN], middle rhombencephalic reticular nucleus [MRRN]), zebrafish (pontine reticular formation, retropontine reticular formation [RetroP]), and salamander (superior reticular nucleus [sRN], middle reticular nucleus [mRN]). Possible homologs of the mammalian medullary RFs are also highlighted in lamprey (posterior rhombencephalic reticular nucleus [PRRN]), zebrafish (medullary reticular formation), and salamander (inferior reticular nucleus [iRN]). Bottom: schematic illustrations of transverse slices at the level of the mesencephalic locomotor region (MLR). Efficient MLR stimulation sites colocalize with cholinergic neurons (positive for choline acetyltransferase [ChAT]) of the pedunculopontine nucleus in mammals, the pedunculopontine nucleus and laterodorsal tegmental nucleus in lamprey and salamander, and a putative homolog ChAT⁺ cell group in zebrafish. This indicates that MLR neurons generating the locomotor drive are consistently located around the cholinergic population in vertebrates. (F–H) Electrical stimulation of the MLR evokes swimming in a lamprey semi-intact preparation, in which the brain is accessible and the body is free to move (adapted from Brocard and others 2010; Ryczko and others 2020) and in larval zebrafish with the head embedded in agarose and the body free to move (adapted from Carbo-Tano and others 2022). In a salamander semi-intact preparation, low-intensity MLR stimulation evokes walking, and higher stimulation intensities evoke swimming (adapted from Cabelguen and others 2003). In rats and mice, electrical stimulation of the MLR evokes walking movements on ground and swimming movements underwater (adapted from Bachmann and others 2013; see also Roussel and others 2022). CnF, cuneiform nucleus; PPN, pedunculopontine nucleus.

Because of its ubiquity in vertebrates, the MLR became a potential target to stimulate in diseases with locomotor deficits. For instance, in Parkinson disease (PD), locomotor deficits (akinesia, gait freezing) are associated with decreased activity in the MLR (for review, Ryczko and Dubuc 2017; Shine and others 2013; Thevathasan and others 2012), suggesting that an increase in MLR activity could alleviate locomotor deficits. Since 2005, the MLR has been explored as a target for deep brain stimulation (DBS) to improve locomotor function in PD (Mazzone and others 2005; Plaha and Gill 2005). The outcome of the initial studies was positive, but these results were not systematically reproduced (e.g., Garcia-Rill and others 2019; Thevathasan and others 2018).

A possible explanation to such variability is that the MLR is a heterogeneous structure. In mammals, it mainly contains the cuneiform nucleus (CnF) dorsally and the pedunculopontine nucleus (PPN) ventrally (Figure 2). Most clinical studies targeted the PPN, leaving the CnF largely unexplored (Chang and others 2020; Goetz and others 2019). These nuclei contain different genetically defined cell types with opposing effects on locomotion. The CnF contains mainly glutamatergic neurons (positive for the vesicular glutamatergic transporter 2 [Vglut2]) and GABAergic neurons (positive for the vesicular GABA transporter [VGAT]). The PPN contains glutamatergic, GABAergic, and cholinergic neurons (positive for choline acetyl transferase [ChAT], an enzyme that synthetizes acetylcholine; Roseberry and others 2016; Figure 2). Although not reviewed here, MLR cells also coexpress neuropeptides, and this likely increases the heterogeneity of cell types (for review, Ryczko and Dubuc 2013). DBS protocols rely on electrical stimulation, which is not yet optimized to selectively activate the MLR neurons that generate the locomotor drive. During the last 8 years, studies in rodents, mainly based on optogenetics and chemogenetics (Box 1), allowed researchers to start dissecting the role of each genetically defined cell type, and the results indicate that some MLR neurons initiate locomotion while others stop locomotion (Figure 2). DBS likely activates a heterogeneous population of neurons around the electrode, including the ones that stop locomotion, and this likely contributes to the variable outcomes. Hence, cell type–specific targeting should refine the behavioral outcomes evoked by MLR stimulation.

Figure 2.

Effects of mesencephalic locomotor region (MLR) cell type stimulation in intact rodents and in rodent models of Parkinson disease (PD). Left: illustration of a slice of the mouse brain at the level of the MLR. The dorsal part (cuneiform nucleus [CnF]) and the ventral part (pedunculopontine nucleus [PPN]) are delineated. On the right, the locomotor (loco) effects resulting from optogenetic (opto) or chemogenetic (chemo) activation of MLR glutamatergic neurons (positive for vesicular glutamate transporter 2 [Vglut2]), GABAergic neurons (positive for vesicular GABA transporter [VGAT]), or cholinergic neurons (positive for choline acetyltransferase [ChAT]) in intact rodents and in rodent animal models of PD. Note that some authors targeted MLR CamKIIa⁺ neurons (e.g., Carvalho and others 2020), among which many but not all are glutamatergic (Kreeger and others 2021; Meng and others 2016; Roseberry and others 2016; Wang and others 2013). Also note that the first studies targeted the MLR at large, without precisely targeting the CnF or PPN (Capelli and others 2017; Lee and others 2014; Roseberry and others 2016).

Box 1.

Selectivity and time scales of Electrical Stimulation versus Optogenetic or Chemogenetic Stimulation.

(A) When one aims to stimulate a specific cell population, electrical stimulation has limited selectivity because the current delivered spreads all around the electrode, thus recruiting neurons nearby the electrode. The effects of electrical deep brain stimulation (DBS) are in the order of the millisecond, as shown by the spiking activity illustrated at the bottom.

(B) With optogenetics, genetically defined cell populations are made to express a light-sensitive ion channel, which makes those cells sensitive to light. Then, when light is shone in the target region, only the neurons expressing the light-sensitive ion channel are activated. Some light-sensitive ion channels can be used to activate neurons—such as channelrhodopsin (ChR2), sensitive to ~470-nm blue light, or ChrimsonR, a red-shifted channelrhodopsin sensitive to ~590-nm yellow light, whereas other ones can be used to inhibit neurons, including halorhodopsin, a chloride pump sensitive to ~580-nm yellow light (for review, Kim and others 2017). In terms of time scale, optogenetics is precise and allows the experimenter to switch neurons on or off from a few milliseconds to dozens of seconds or minutes.

(C) With chemogenetics, genetically defined cell populations are made to express a modified version of the human muscarinic receptor, which is sensitive to a drug (clozapine N-oxide) designed to activate this receptor. These receptors are thus called designer receptors exclusively activated by designer drugs (DREADD). Then, when the designer drug is delivered in the target brain region, only the cells expressing the DREADD will be activated. Some DREADD can be used to activate neurons, whereas others can be used to inhibit neurons (for review, Roth 2016). In terms of time scale, chemogenetics allows tonic activation or inhibition of the target neurons during dozens of minutes to an hour.

To help define the best cell type to stimulate in the MLR to improve locomotor function in pathologic conditions, here I review recent studies that reported the effects of selective stimulation of MLR cell types in intact animals and in animal models of PD. For further reading about the MLR, I refer to recent reviews on brainstem circuits controlling locomotor initiation, speed, stop, and steering movements (Leiras and others 2022), on the functional relations between brainstem motor circuits and the basal ganglia (Arber and Costa 2022), on MLR DBS in spinal cord injury (Noga and Guest 2021) and on state-dependent control of locomotion by brainstem motor circuits (Noga and Whelan 2022; Pernia-Andrade and others 2021).

Targeting the MLR at Large by Using Molecular Tools: The First Studies

The first optogenetic stimulation of the MLR at large (i.e., without precisely targeting the CnF or PPN) was done by injecting in the MLR an adeno-associated virus driving the expression of channelrhodopsin (Box 1) under control of the calcium/calmodulin-dependent protein kinase IIa promoter (CamKIIa; Lee and others 2014). CamKIIa is expressed in glutamatergic neurons (Vglut2⁺) but also in a minority of nonglutamatergic ones (Kreeger and others 2021; Meng and others 2016; Roseberry and others 2016; Wang and others 2013). Optogenetic stimulation of MLR CamKIIa⁺ neurons evoked locomotion in head-fixed mice placed on a trackball (Lee and others 2014). In this study, the firing of a fraction of MLR cells was correlated with locomotor speed. Optogenetic activation of CamKIIa⁺ MLR cells also increased visually evoked responses in the visual cortex, though ascending projections to cholinergic neurons in the basal forebrain that send input to the visual cortex (Lee and others 2014).

Roseberry and others (2016) performed selective optogenetic activation of Vglut2⁺, VGAT⁺, or ChAT⁺ neurons of the MLR at large using transgenic mice coupled with adeno-associated virus injections. In head-fixed mice placed on a trackball, they showed the following: 1) optogenetic activation of MLR Vglut2⁺ neurons evoked locomotion and control locomotor speed; 2) the electrophysiologic activity of a fraction of Vglut2⁺ neurons correlated with locomotor speed; 3) optogenetic inhibition of MLR CamKIIa⁺ neurons decreased locomotor speed; 4) optogenetic activation of MLR VGAT⁺ neurons stopped locomotion; and 5) optogenetic activation of MLR ChAT⁺ neurons slightly increased the speed of ongoing locomotion. They also established that activation of striatal neurons of the direct and indirect pathways respectively increased or decreased locomotion by controlling the firing of CamKIIa⁺ MLR neurons.

Capelli and others (2017) identified some of the downward targets of MLR Vglut2⁺ neurons. Using adeno-associated virus injections in Vglut2-cre mice, they showed that ablation of Vglut2⁺ neurons in the lateral paragigantocellular nucleus (LPGi) reduced the speed of locomotion evoked by optogenetic stimulation of Vglut2⁺ MLR neurons in freely moving mice. Altogether these studies provided key information about the rodent MLR and laid the foundation for further dissection of the genetically defined cell populations in the PPN and CnF, as described below.

CnF Vglut2⁺ Neurons: Slow and Fast Gaits

Stimulation

Optogenetic activation of CnF Vglut2⁺ neurons controlled the initiation of locomotion and all locomotor speeds in mice, and this effect was robust from laboratory to laboratory (Caggiano and others 2018; Dautan and others 2021; Fougère and others 2021; Josset and others 2018; van der Zouwen and others 2021; Masini and Kiehn 2022; Figure 3A and B). During optogenetic experiments, an increase in laser power or stimulation frequency increased locomotor speed or elicited transitions between slow gaits (walking, trotting) and fast gaits (gallop, bound) in a linear corridor (Caggiano and others 2018), a motorized treadmill (Josset and others 2018), or an open field (Dautan and others 2021; Fougère and others 2021; van der Zouwen and others 2021; Figure 3C). Importantly, the footfall pattern and the limb kinematics evoked by stimulation of CnF Vglut2⁺ neurons were very close to those recorded in the same animals during spontaneous locomotion (van der Zouwen and others 2021; Figure 3D and E). Optogenetic stimulation of CnF Vglut2⁺ neurons did not prevent mice from slowing down and turning when approaching a wall in an open field (van der Zouwen and others 2021; Figure 3G–I). The motor signature of the slowing down during turning was close to the one reported when stimulating the steering circuitry, which comprises reticular V2a neurons that receive visual information from the superior colliculus, a direct target of retinal ganglion cells (Bouvier and others 2015; Cregg and others 2020; Usseglio and others 2020). This indicates that during stimulation of CnF Vglut2⁺ neurons, integration of visual inputs is still possible, ensuring adaptable navigation (van der Zouwen and others 2021). This is consistent with the ability of mice to navigate in a hole board during CnF Vglut2⁺ optogenetic stimulation (Caggiano and others 2018).

Figure 3.

Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus controls locomotion in intact mice. (A–C) In an open field, blue light (470 nm) shone with a laser in the cuneiform nucleus (CnF) of mice expressing the ion-sensitive channel channelrhodopsin in glutamatergic neurons (positive for the vesicular glutamatergic transporter 2 [Vglut2]) evoked locomotion. Increasing laser power increased locomotor speed. Each data point is the average of 3 to 5 mice. (B) Data are presented as mean (black) ± SEM (grey). (C) Data are presented as mean ± SEM. Black line, sigmoidal fit; dotted lines, 95% prediction intervals. (D) In a linear corridor, the footfall pattern evoked by optogenetic stimulation of CnF Vglut2⁺ neurons was similar to that recorded during spontaneous locomotion. Each rectangle represents the normalized duration of the stance phase for each limb. (E, F) In a linear corridor, the hindlimb kinematics evoked by optogenetic stimulation of CnF Vglut2⁺ neurons were similar to those recorded during spontaneous locomotion. (F) Time elapsed from first to last frame is 700 ms (top) and 500 ms (bottom). (G, H) During tonic optogenetic stimulation of CnF Vglut2⁺ neurons, multiple slow-downs were smoothly achieved (highlighted with white filled dots). (I) The slow-downs were happening when the mouse was approaching the walls of the arena, indicating that dynamic integration of visual inputs and generation of steering commands by the distinct steering circuitry (Cregg and others 2020; Usseglio and others 2020) are still possible during tonic stimulation of Vglut2⁺ CnF neurons. Panels A–I adapted from van der Zouwen and others (2021). FL, forelimb; HL, hindlimb; MTP, metatarsophalangeal.

Inhibition

Optogenetic inhibition of CnF Vglut2⁺ neurons slowed down ongoing locomotion on a motorized treadmill (Josset and others 2018). Another team reported that optogenetic inhibition of MLR Vglut2⁺ neurons impeded running, although the distinction between CnF and PPN was not done (Roseberry and others 2016). Chemogenetic inhibition of CnF Vglut2⁺ neurons decreased the ability of mice to use the fastest gaits (Caggiano and others 2018), reduced locomotor speed during escape, and lowered maximal acceleration without affecting the use of slower speed ranges during exploratory locomotion in an open field (Masini and Kiehn 2022). Chemogenetic inhibition of CnF Vglut2⁺ neurons did not prevent the prolocomotor effects of chemogenetic activation of caudal PPN Vglut2⁺ neurons (Masini and Kiehn 2022).

Activity during Behavior

There was a positive correlation between locomotor speed and the firing frequency of some mouse CnF Vglut2⁺ neurons recorded extracellularly during long bouts of locomotion (30–60 s) on a motorized treadmill (Caggiano and others 2018). However, only a fraction of MLR neurons encoded locomotion speed overall (for review, Arber and Costa 2022; Caggiano and others 2018; Carvalho and others 2020; Ferreira-Pinto and others 2021; Roseberry and others 2016).

Cell Properties

CnF Vglut2⁺ neurons have homogeneous electrophysiologic properties (Dautan and others 2021). Most are fast-adapting neurons, lack persistent sodium currents, and display weak-amplitude, tetrodotoxin-resistant oscillating properties of their membrane potential in the 20- to 40-Hz range. CnF Vglut2⁺ neurons have a more complex dendritic structure than PPN Vglut2⁺ ones (Dautan and others 2021).

Target-Specific Effects

CnF Vglut2⁺ neurons control locomotion through projections to multiple reticular nuclei (Figure 4A), including the LPGi, gigantocellular nucleus (Gi), gigantocellular reticular nucleus alpha part (GiA), gigantocellular reticular nucleus ventral part (GiV), and caudal raphe nuclei, which all contain reticulospinal neurons (Bretzner and Brownstone 2013; Caggiano and others 2018; Capelli and others 2017), although the CnF/PPN distinction was not systematically made (for review, Arber and Costa 2022; Leiras and others 2022). Optogenetic stimulation of the Vglut2⁺ terminals originating from the MLR and targeting the LPGi evoked locomotion in mice (Capelli and others 2017). Vglut2⁺ neurons retrogradely labeled in the MLR from the LGPi evoked locomotion when optogenetically stimulated, and most of these neurons resided in the CnF (Capelli and others 2017). CnF projections to other reticular nuclei are likely functional, since CnF electrical stimulation evoked excitatory responses in gigantocellular nucleus V2a neurons recorded via calcium imaging in mice (Bretzner and Brownstone 2013).

Figure 4.

Functional outputs of (A) the cuneiform nucleus (CnF) and (B) the pedunculopontine nucleus (PPN). Note that only the projections tested functionally with genetic tools on rodents were included here, but more anatomical projections were reported. For instance, the descending cholinergic projections of the PPN are well established (Gut and Mena-Segovia 2019; Mena-Segovia and Bolam 2017; for review, Ryczko and Dubuc 2013). For the sake of simplicity, in the CnF and PPN, all cells with the same transmitter were pooled in a single circle. The interconnectivity among mesencephalic locomotor region cell types and whether the different projection patterns originate from distinct populations of neurons are not fully resolved. The green question mark highlights that it is not known whether this CamKIIa⁺ projection to BF originates from PPN or CnF, because the distinction was not made in Lee and others (2014). For details about the behavioral role of these projections, see main text. BF, basal forebrain; Cardio, cardiovascular; Entorh, entorhinal; Gi, gigantocellular nucleus; GPe external globus pallidus; HDB, horizontal limb of the diagonal band of Broca; LPGi, lateral paragigantocellular nucleus; Respi, respiratory; RS, reticulospinal; SNc, dopaminergic neurons of the substantia nigra pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus; Thalam, thalamus; VTA, dopaminergic neurons of the ventral tegmental area. The brain picture was kindly provided by GENSAT and previously used as a background image in Fougère and others (2019).

Beyond locomotion, CnF glutamatergic neuron activation increased respiration in mice (Hérent and others 2021). CnF Vglut2⁺ neurons project to the pre-Bötzinger complex, where part of the respiratory central pattern generator resides (Hérent and others 2021). Optogenetic stimulation of CnF Vglut2⁺ neurons increases the respiratory rhythm, even in the absence of locomotion (Hérent and others 2021). These projections are likely phylogenetically old, since in lamprey, glutamatergic projections originating from the dorsal part of the MLR (the possible homolog of the CnF) increased respiration (Gariépy and others 2012). The CnF also regulates cardiovascular activity (for review, Noga and Whelan 2022; Ryczko and Dubuc 2013). DBS of the MLR increases heart rate, and this seems to be an indicator of successful CnF targeting (rat, Korte and others 1992; cat, Opris and others 2019; pig, Chang, Santamaria, and others 2021). The pathway involved likely comprises projections from the CnF to the LPGi; these would send input to raphe magnus 5-HT neurons, which modulate the nucleus of the solitary tract in mice (Netzer and Sevoz-Couche 2021).

Stimulation in a PD Model

In mice, intrastriatal injections of the neurotoxin 6-hydroxydopamine (6-OHDA) destroyed dopaminergic neurons (Figure 5A–C) and decreased spontaneous locomotion (Figure 5E and F; Fougère and others 2021). Although 6-OHDA does not mimic the chronic aspect of the degeneration observed in PD, it is useful for the preclinical evaluation of potential therapeutic interventions (Duty and Jenner 2011). In this type of PD model, optogenetic stimulation of CnF Vglut2⁺ neurons increases the time spent in locomotion, the number of locomotor initiations, and the locomotor speed (Figure 5E–H). The hindlimb joint angular excursions are largely similar to those recorded before the 6-OHDA lesion (Figure 5K and L). The level of CnF Vglut2⁺ neuron activation positively controls locomotor speed in such PD conditions (Figure 5I and J), and mice can slow down and turn when approaching a wall of the open field (Figure 5E and F; Fougère and others 2021) as in intact mice (van der Zouwen and others 2021).

Figure 5.

Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus (CnF) controls locomotion in a mouse model of Parkinson disease. (A–D) To model Parkinson disease, a neurotoxin (6-hydroxydopamine [6-OHDA]) was injected in the striatum of mice expressing the ion-sensitive channel channelrhodopsin and the fluorescent protein EYFP in glutamatergic neurons (positive for the vesicular glutamatergic transporter 2 [Vglut2]). In control mice, only a vehicle solution was injected in the striatum. Intrastriatal 6-OHDA destroyed dopaminergic fibers positive for tyrosine hydroxylase in the striatum, but intrastriatal vehicle solution did not. An optic fiber was implanted in the CnF and connected to a laser-generating blue light (470 nm) to activate CnF Vglut2⁺ neurons. (E, F) In an open field, mouse locomotion was filmed from above during optogenetic stimulation (10 s, blue lines) and in between stimulations (80 s, black lines). Between optogenetic stimulations, spontaneous locomotion was severely lowered in 6-OHDA mice as compared with control mice, in which dopaminergic neurons were not destroyed. (G, H) Optogenetic stimulation of CnF Vglut2⁺ neurons increased locomotor speed (mean ± SEM) in 6-OHDA mice as in control mice. (I, J) Increasing laser power increased locomotor speed in 6-OHDA mice as in control mice. Data are presented as mean ± SEM. Black line, sigmoidal fit; dotted lines, 95% CI. (K, L) In a linear corridor, hindlimb kinematics were filmed from the side and analyzed with DeepLabCut (see also Figure 3E). The angle excursions (mean ± SD) in the hip, knee, ankle, and metatarsophalangeal (MTP) joints during locomotion evoked by optogenetic stimulation of CnF Vglut2⁺ neurons were largely similar to those recorded during spontaneous locomotion before the destruction of dopaminergic neurons. In control mice, hindlimb joint angle excursions (mean ± SD) during locomotion evoked by optogenetic stimulation of CnF Vglut2⁺ neurons were largely similar to those recorded during spontaneous locomotion before the injection of a vehicle solution in the striatum. Panels A–L adapted from Fougère and others (2021). IC, inferior colliculus; PAG, periaqueductal gray.

In another mouse PD model based on systemic injections of dopaminergic antagonists, chemogenetic activation of CnF Vglut2⁺ neurons increased locomotor activity (Masini and Kiehn 2022). Evoked behavior consists of succession of high-speed locomotion and long stops, reminiscent of a “darting” behavior, which is displayed when animals try to avoid a predator (Masini and Kiehn 2022). Such behavior is consistent with the inputs to the CnF, which are associated with defensive behavior (Caggiano and others 2018; Dautan and others 2021; for review, Leiras and others 2022; Ryczko and Dubuc 2013). In contrast, chemogenetic stimulation of PPN Vglut2⁺ neurons produced more continuous slow-speed locomotion in the same PD model (Figure 6; Masini and Kiehn 2022; see Stimulation in a PD Model in PPN Vglut2⁺ Neurons section).

Figure 6.

Chemogenetic activation of glutamatergic (Vglut2⁺) or GABAergic (VGAT⁺) neurons in the caudal pedunculopontine nucleus has different effects on locomotion in mouse models of Parkinson disease (PD). (A) To model the akinesia seen in PD, Masini and Kiehn (2022) injected intraperitoneally in mice a D2 antagonist (haloperidol) or a D1 antagonist (SCH 23390). (B) Calcium activity of striatal neurons were measured with a miniaturized microscope coupled with a GRIN lens positioned above the dorsal striatum (STR) of D1-cre mice injected in the STR with an adeno-associated virus expressing the genetically encoded calcium sensor GCaMP6s in a cre-dependent manner. (C) Top left: field of view showing neurons expressing GCaMP6s in white (scale 100 μm). Top right: coronal section illustrating lens position above the dorsal STR (scale 1 mm), with GCamP6s in magenta and neurotrace in black. The lower panel presents a typical example of calcium activity (Z score) from four cells in the field of view after intraperitoneal application of a D2 antagonist (haloperidol). (D) Distance moved in the open field before and after the dopaminergic antagonist injection. Individuals are represented by thin lines; group mean ± SEM are in black. (E, I) Viral strategies to bilaterally express excitatory DREADD in caudal pedunculopontine nucleus (PPN) Vglut2⁺ neurons or caudal PPN VGAT⁺ neurons. (F, J) Top: representative trajectory of the animal in the open field (scale, 25 cm) after DREADD activation. Bottom: instantaneous speed of the animal following DREADD activation in PPN Vglut2⁺ or VGAT⁺ neurons. Stop events in absence of in-place behavior are illustrated by red dots. (G, H, K, L) Timeline effect of D1 or D2 antagonist before (light gray background) and after (gray) DREADD activation in sham. Vglut2-cre mice injected in the caudal PPN with DREADD (green) and VGAT-cre mice injected in the caudal PPN with DREADD (blue). Two-way repeated measures analysis of variance with graph reporting group effect and analysis done for each period (i.e., before and after DREADD activation). Data are presented as mean ± SEM. ns, not significant. *P < 0.05. **P < 0.01. ***P < 0.001. (M, N) Hindlimb kinematics were filmed from the side, and the angular excursions in the knee and ankle joints were analyzed with DeepLabCut. (O) Angular excursions (mean ± 95% CI) of knee and ankle joints during a complete locomotor cycle. Panel A adapted from van der Zouwen and others (2021). Panel B adapted from Fougère and others (2021). Panels C–O adapted from Masini and Kiehn (2022). CNO, clozapine N-oxide; DREADD, designer receptors exclusively activated by designer drugs.

Altogether this indicates that CnF Vglut2⁺ neurons are a relevant target to improve locomotor function and control locomotor speed, without disrupting the ability to slow down and turn during navigation in PD conditions. Vglut2⁺ neurons are present in the human MLR according to immunohistochemistry and in situ hybridization, but their degeneration status in PD needs further investigation (Sébille and others 2019). CnF Vglut2⁺ neurons were recently identified as a relevant target to improve locomotor function after partial spinal cord injury in mice (Roussel and others 2022).

CnF VGAT Neurons: Locomotor Arrests

Optogenetic stimulation of CnF VGAT⁺ neurons stopped ongoing locomotion in mice walking on a motorized treadmill (Caggiano and others 2018). In line with this, optogenetic activation of MLR VGAT⁺ neurons decreased walking speed on a trackball in mice, although the distinction between CnF and PPN was not done (Roseberry and others 2016). In vivo extracellular recordings showed that optogenetic stimulation of MLR VGAT⁺ neurons reduced the spiking of non-GABAergic (thus possibly glutamatergic) neurons (Roseberry and others 2016). Although the selective manipulation of CnF VGAT⁺ neurons was not tested in an animal of PD, it is likely that activation of these neurons should worsen the locomotor deficits.

PPN Vglut2⁺ Neurons: Slow Gaits, Posture Adjustments, and Locomotor Arrests

Stimulation

As compared with the CnF, PPN neurons have a more complex projection pattern (Figure 4B). More variable outcomes were reported when PPN neurons were stimulated. PPN Vglut2⁺ neurons were first noted to evoke slow locomotor gaits in a linear corridor (walking and trotting) but not fast gaits (Caggiano and others 2018). Higher intensity of photostimulation of PPN Vglut2⁺ led to higher speed (Caggiano and others 2018). Chemogenetic activation of the caudal PPN Vglut2⁺ increased low-speed locomotor activity in an open field and reduced the number of stops per time unit relative to the control condition (Masini and Kiehn 2022). PPN Vglut2⁺ neurons stimulation also increased exploratory locomotion in the hole board test, in which exploration was motivated by olfactory cues from conspecifics (Caggiano and others 2018). Interestingly, environment scanning during locomotion was occasionally cited during electrical stimulation of the MLR in pigs (Chang, Santamaria, and others 2021). Another team reported that chemogenetic activation of PPN Vglut2⁺ neurons promoted wakefulness and mild anxiety, and this translated to increased locomotor activity on a running wheel placed in mouse home cages during daytime (i.e., when mice are supposed to be quieter and are about to sleep; Kroeger and others 2017).

Activation of PPN Vglut2⁺ neurons can also stop locomotion or have no effect on locomotor activity. A first team reported that optogenetic stimulation of PPN Vglut2⁺ neurons did not initiate locomotion but slowed down or stopped ongoing locomotion on a motorized treadmill in mice (Josset and others 2018). A second team showed that optogenetic activation of PPN Vglut2⁺ neurons did not initiate locomotion, slowed down ongoing locomotion on a motorized treadmill, and reduced the distance traveled in an open field (Dautan and others 2021). When mice were placed on an elevated grid, optogenetic activation of PPN Vglut2⁺ neurons reduced the distance traveled, decreased the number of rearing events, and increased foot slips (Dautan and others 2021). A third team indicated that in rats optogenetic stimulation of PPN CamKIIa⁺ neurons (among which most but not all are glutamatergic; Kreeger and others 2021; Meng and others 2016; Roseberry and others 2016; Wang and others 2013) increased locomotion in 76% of animals but slowed down or stopped locomotion in 24% of animals, thus somehow recapitulating the variability of behavioral outcomes (Carvalho and others 2020). Altogether, this indicates that multiple groups of Vglut2⁺ neurons are present in the PPN and they likely control different aspects of motor behavior. Targeting Vglut2⁺ neurons in the caudal PPN is important to evoke prolocomotor effects (Figure 6; Caggiano and others 2018; for review, Leiras and others 2022; Masini and Kiehn 2022).

Inhibition

Optogenetic inhibition of PPN Vglut2⁺ neurons stopped locomotion in most trials or slowed down locomotion by increasing hindlimb extensor activity on a motorized treadmill in mice (Josset and others 2018). Optogenetic inhibition of PPN Vglut2⁺ neurons did not increase the distance traveled in an open field and did not decrease foot slips in the elevated grid (Dautan and others 2021). CnF Vglut2⁺ neurons can evoke all gaits independently of PPN Vglut2⁺ neurons: when PPN Vglut2⁺ neurons are inhibited through chemogenetics, optogenetic stimulation of CnF Vglut2⁺ neurons can still evoke all gaits, including gallop and bound, nevertheless with a reduction in the maximal locomotor speed (Caggiano and others 2018).

Activity during Behavior

During long bouts of locomotion on a motorized treadmill (30–60 s), 1) some PPN Vglut2⁺ were activated at the beginning of the locomotor bout and decreased their activity thereafter; 2) some showed no correlation with locomotor speed; and 3) some showed a correlation with locomotor speed (Caggiano and others 2018; see also Roseberry and others 2016, although the CnF/PPN distinction was not done). Extracellular electrophysiological recordings of nonidentified PPN cells showed that 29% of neurons correlated positively and 17% negatively with locomotor speed. Overall, only a fraction of PPN cells correlated with locomotor speed (Carvalho and others 2020; Norton and others 2011). This is in line with recent work showing heterogeneity in the behavioral effects evoked by the stimulation of different cell types in the PPN: some PPN glutamatergic neurons projecting to the spinal cord encoded body rearing, and others projecting to an output station of the basal ganglia encoded forelimb movements such as handling and grooming (Ferreira-Pinto and others 2021).

Cell Properties

PPN Vglut2⁺ neurons are more heterogeneous than CnF ones (Dautan and others 2021). Examination of their firing pattern indicated that 86% of CnF neurons are fast adapting, while in the PPN, 49% are fast adapting, 21% are slow adapting, and 30% are nonadapting (Dautan and others 2021). PPN Vglut2⁺ neurons display high-amplitude, tetrodotoxin-sensitive oscillations of their membrane potential in the 10- to 20-Hz range. Most PPN Vglut2⁺ neurons express persistent sodium currents, contrary to CnF ones. PPN Vglut2⁺ dendritic trees are less complex than CnF ones (Dautan and others 2021). Whether such variability goes hand in hand with the variety of projections and/or behavioral outcomes remains to be examined.

Target-Specific Effects

It is likely that the diversity of behavioral outcomes occurring when stimulating PPN Vglut2⁺ neurons involves different projection neurons (Figure 4B).

A first set of projections from PPN Vglut2⁺ neurons provided descending input to several reticular nuclei (Caggiano and others 2018) that contain different reticulospinal neurons able to shape locomotor pattern and rhythm in the freely behaving mouse (Lemieux and Bretzner 2019; Figure 4B). Future studies should determine whether PPN Vglut2⁺ neurons segregate to either target V2a neurons responsible for locomotor stops (Bouvier and others 2015; Cregg and others 2020; Usseglio and others 2020) or reticulospinal neurons in the LPGi that convey the locomotor drive to the spinal cord (Capelli and others 2017). This is possible since in zebrafish, electrical stimulation of the MLR activated diverse populations of V2a reticulospinal neurons (Carbo-Tano and others 2022). In lamprey, reticulospinal “stop cells” (Juvin and others 2016) were under control of direct glutamatergic input from the MLR (Grätsch and others 2019).

A second projection from PPN Vglut2⁺ neurons targets the striatum (Figure 4B), avoids spiny projection neurons, and directly connects striatal cholinergic interneurons and GABAergic fast-spiking interneurons (Assous and others 2019). Unilateral activation of PPN Vglut2⁺ results in disynaptic inhibition of medium spiny neurons and evokes head turns ipsilaterally to PPN stimulation.

A third projection of PPN Vglut2⁺ neurons targets dopaminergic neurons of the substantia nigra pars compacta (SNc; Figure 4B). Optogenetic stimulation of these axons evoked spiking in SNc dopaminergic neurons (Galtieri and others 2017). This pathway is well positioned to increase locomotor output since activation of SNc dopaminergic neurons increases the vigor of future movement (da Silva and others 2018; Howe and Dombeck 2016).

A fourth projection of PPN Vglut2⁺ neurons targets dopaminergic neurons of the ventral tegmental area (VTA; Figure 4B). Optogenetic stimulation of this pathway promoted behavioral reinforcement in an intracranial self-stimulation task, during which the animal could introduce its nose in a hole to trigger optogenetic stimulation of PPN Vglut2⁺ terminals in the VTA (Yoo and others 2017).

A fifth projection from PPN Vglut2⁺ neurons targets the spinal cord and encodes rearing in mice. Its activation induced body stretching whereas deactivation shortened body length (Ferreira-Pinto and others 2021).

A sixth projection of likely Vglut2⁺ neurons located in the PPN and adjacent mesencephalic reticular formation targets the substantia nigra pars reticulata (Ferreira-Pinto and others 2021), an output station of the basal ganglia that inhibits the MLR (Roseberry and others 2016; Figure 4B). These neurons express the genetic marker Rbp4, are ChAT^– and VGAT^– (thus likely Vglut2⁺), and their activation terminated locomotion (Ferreira-Pinto and others 2021).

A possible seventh projection of PPN CamKIIa⁺ neurons (among which most but not all are glutamatergic; Kreeger and others 2021; Meng and others 2016; Roseberry and others 2016; Wang and others 2013) would target the horizontal limb of the diagonal band of Broca in the basal forebrain, which sends input to the entorhinal cortex (Carvalho and others 2020; Figure 4B). This pathway likely provides speed-related information to update the representation of the animal’s position in the environment during navigation. Future studies should identify whether a mix of Vglut2⁺ and VGAT⁺ PPN neurons is involved because ascending PPN inputs produce excitation and inhibition in the basal forebrain (Carvalho and others 2020).

A possible eighth projection of PPN CamKIIa⁺ neurons would target cholinergic neurons in the basal forebrain that send input to the visual cortex (Lee and others 2014; Figure 4B). Activation of these CamKIIa⁺ neurons increases the gain of cortical cells responding to visual stimuli. Future studies should identify whether PPN and/or CnF Vglut2⁺ neurons are involved because the distinction was not made (Lee and others 2014).

Stimulation in a PD Model

In mouse models of PD based on systemic injection of dopaminergic antagonists (Figure 6A–D), optogenetic or chemogenetic stimulation of Vglut2⁺ neurons in the caudal PPN increased slow exploratory locomotion in an open field (Masini and Kiehn 2022; Figure 6E–H). The limb kinematics evoked by such stimulations were largely normal when angular excursions in the knee and ankle were measured (Figure 6M–O). Mice could climb stairs or avoid pillars on the way, showing that activation of caudal PPN Vglut2⁺ neuron allows for adaptable navigation, as CnF Vglut2⁺ neurons do (Fougère and others 2021; van der Zouwen and others 2021). The prolocomotor effect of caudal PPN Vglut2⁺ neurons was independent of CnF Vglut2⁺ neurons that were deactivated through chemogenetics in those experiments (Masini and Kiehn 2022). This indicates that a subtype of PPN Vglut2⁺ neurons constitutes a relevant target to improve locomotor function in PD conditions. Further investigation is needed to understand which PPN cell subtype promotes locomotion and which inhibits locomotion. The superiority of the caudal PPN over the rostral PPN as a target to evoke locomotion is consistent with previous literature. In parkinsonian rats, DBS of the anterior PPN worsened gait, whereas DBS of the caudal PPN improved gait (Gut and Winn 2015). This is consistent with the rostral PPN containing more GABA neurons projecting to the basal ganglia and the caudal PPN containing more glutamatergic neurons projecting to reticular nuclei (for review, Martinez-Gonzalez and others 2011; Mena-Segovia and Bolam 2017; Ryczko and Dubuc 2013).

PPN GABAergic Neurons: Locomotor Arrests and Slow Segmented Locomotion

Stimulation

As for PPN Vglut2⁺ neurons, there is some variability in the locomotor effects evoked by activation of PPN VGAT⁺ neurons, and this may be linked to the diverse targets of these neurons (Figure 4B). The duration of the stimulation train can produce different behavioral outcomes. Relatively short optogenetic activation of PPN VGAT⁺ neurons (2-s trains) did not evoke locomotion and slowed down ongoing locomotion of mice in a linear corridor (Caggiano and others 2018). In line with this, locomotor speed was decreased by optogenetic activation (5-s trains) of MLR VGAT⁺ neurons in mice walking on a trackball, although the difference between PPN and CnF was not made (Roseberry and others 2016). In contrast, longer periods of optogenetic stimulation (10-s trains) or chemogenetic activation of PPN VGAT⁺ neurons could initiate locomotion and evoke a modest increase in the distance traveled in an open field, but the locomotor bouts were interrupted by abundant short stops (Masini and Kiehn 2022). The decrease in locomotion evoked by PPN VGAT⁺ neurons reported by Caggiano and colleagues (2018) may have involved local projections to PPN Vglut2⁺ neurons (Roseberry and others 2016), whereas the prolocomotor effect reported by Masini and Kiehn (2022) could have involved ascending inhibition of the subthalamic nucleus (Guillaumin and others 2021; Schweizer and others 2014), which sends excitatory input to the output stations of the basal ganglia that inhibit PPN Vglut2⁺ neurons (Masini and Kiehn 2022).

Target-Specific Effects

PPN VGAT⁺ neurons send ascending projections to SNc dopaminergic neurons and, to a lesser extent, to VTA (Gut and others 2022; Figure 4B). Optogenetic stimulation of PPN VGAT⁺ inputs to SNc decreased striatal dopamine release, reduced the distance traveled in the open field, and increased rearing, but it did not prevent the animal from doing other behaviors, such as rotarod locomotion, pasta handling and eating, or aversive conditioning (Gut and others 2022). However, activation of PPN VGAT⁺ projections to SNc interfered with the initiation of a prelearned motor sequence (Gut and others 2022).

Stimulation in a PD Model

Chemogenetic or optogenetic stimulation of caudal caudal PPN VGAT⁺ neurons could increase locomotor activity in mice made parkinsonian by systemic injection of a D2 dopaminergic antagonist but not in mice made parkinsonian with a D1 antagonist (Figure 6I–L; Masini and Kiehn 2022). The prolocomotor effect is less strong than when caudal PPN Vglut2⁺ neurons or CnF Vglut2⁺ neurons are stimulated (Masini and Kiehn 2022). Caudal PPN VGAT⁺ neuron activation induced rather abnormal limb movements, such as longer stance phase and limb joint hyperextension (Figure 6M–O), and reduced hindlimb-forelimb coordination during the ladder test (Masini and Kiehn 2022). Altogether, PPN VGAT⁺ neurons are likely not the best neurons to stimulate to improve locomotor function in PD conditions, since they either stop locomotion or evoke segmented locomotor bouts, and the evoked limb movements are not normal.

PPN Cholinergic Neurons: A Complex Role

Stimulation

The role of PPN cholinergic neurons is still unresolved, maybe because these cells have diverse and complex projection patterns as well (for review, Mena-Segovia and Bolam 2017; Figure 4B). Optogenetic stimulation of PPN ChAT⁺ neurons slightly increased the speed of ongoing locomotion, but such effect was much weaker than that evoked by MLR Vglut2⁺ neurons (Roseberry and others 2016). In contrast, optogenetic stimulation of PPN ChAT⁺ neurons slightly decreased ongoing locomotor speed in a linear corridor in mice (Caggiano and others 2018) or slowed down locomotion by increasing motor tone in hindlimb extensors, thus increasing stance phase duration (Josset and others 2018). In the three aforementioned studies, optogenetic activation did not initiate locomotion. Chemogenetic activation of PPN ChAT⁺ neurons did not affect the distance traveled in an open field in mice (Ruan and others 2022). This is in contrast with the prolocomotor effect of PPN ChAT⁺ neurons noted in PD conditions in rats (see Stimulation in a PD Model in the PPN Cholinergic Neurons section; Pienaar, Gartside, and others 2015; Sharma and others 2020).

Inhibition

Variable results were reported. Optogenetic inhibition of PPN ChAT⁺ neurons decreased spontaneous locomotion in the open field in rats (Xiao and others 2016). Optogenetic inhibition of PPN ChAT⁺ neurons slowed down by increasing extensor burst duration, and this slowing down effect was surprisingly similar to that resulting from their optogenetic activation (Josset and others 2018). Chemogenetic inhibition of PPN ChAT⁺ neurons did not change the distance traveled in an open field in rats (Dautan and others 2020) and mice (Ruan and others 2022).

Lesion

The effect of lesioning PPN cholinergic neurons in rats depends on the task. It was reported to impair performance in complex motor tasks such as the accelerating rotarod (MacLaren and others 2014, Xiao and others 2017). Destruction of PPN cholinergic neurons in rats also increased the paw print area, the speed at which the paw transitioned to next floor contact (suggesting postural instability), and freezing in rats walking on a catwalk (Chambers and others 2021). In contrast, another team indicated that PPN cholinergic lesion did not induce gait disturbance in the CatWalk test but aggravated the locomotor deficits resulting from a lesion of dopaminergic neurons (i.e., increased the number of freezing of gaits and limb dual stance; Xiao and others 2017). In humans with PD, loss of MLR cholinergic neurons was associated with falls, and in monkeys, destruction of PPN cholinergic neurons reproduced the locomotor deficits observed in a PD model based on the destruction of dopaminergic neurons through intoxication with MPTP (Karachi and others 2010).

Activity during Behavior

In vivo extracellular recordings showed that PPN cholinergic neurons changed their activity pattern in relation with brain state transitions, in particular to changes in cortical activity (Mena-Segovia and others 2008). Their activity increased after a pinch of the hindpaw that increased cortical activity, and PPN ChAT⁺ neuron activation preceded cortical activation (for review, Mena-Segovia and Bolam 2017; Petzold and others 2015). PPN cholinergic neurons also responded to rewards, and these responses were influenced by rule switching in the behavioral task (Ruan and others 2022).

Cell Properties

In mice, the rostrocaudal location of the PPN ChAT⁺ neurons correlated with their electrophysiologic properties. Neurons that have high threshold membrane potential oscillations with high frequency (β-γ range, 12–80 Hz) and low power are in the caudal PPN. Neurons that display low-frequency oscillations (α range, 8–12 Hz) and high power are in the rostral PPN. Among neurons displaying a transient outward potassium current (A-current), early- and late-firing neurons could be distinguished, with late-firing ones being more in the caudal PPN (Baksa and others 2019). These cell groups are consistent with those recorded in rats (Mena-Segovia and others 2008; for review, Mena-Segovia and Bolam 2017). Whether these different properties are linked with different projection patterns or behavioral outcomes remains to be examined.

Target-Specific Effects

Here I focus on PPN projections recently tested functionally with genetic tools in rodents (Figure 4B), but additional projections to the basal ganglia or downstream to reticular nuclei are well established (Gut and Mena-Segovia 2019; Mena-Segovia and Bolam 2017; for review, Ryczko and Dubuc 2013). A first target of PPN cholinergic neurons is the striatum (Brimblecombe and others 2018; Dautan and others 2014; Dautan and others 2020; Klug and others 2018), and activation of these ascending cholinergic fibers increased firing in striatal cholinergic interneurons and inhibited spiny projection neurons (Dautan and others 2020). Chemogenetic inhibition of PPN ChAT⁺ projections to the striatum did not change locomotor activity in the open field (Dautan and others 2020).

A second target of PPN ChAT⁺ neurons are mesodiencephalic dopaminergic neurons (SNc/VTA; Figure 4B). The locomotor role of this ascending input is not resolved. Optogenetic activation of PPN cholinergic projections to VTA either increased (Dautan and others 2016) or decreased (Xiao and others 2016) locomotor activity in an open field. Such stimulation was associated with excitation of dopaminergic neurons in rats (Dautan and others 2016). Optogenetic activation of ascending PPN ChAT⁺ projections to SNc increased locomotor activity in an open field, and their inhibition decreased locomotion (Xiao and others 2016). In contrast, another team reported that optogenetic activation of the ascending PPN ChAT⁺ projections to A9 did not modify the distance traveled or locomotor speed in an open field in mice (Ruan and others 2022). The reason for such discrepancy is unclear.

A third target of PPN cholinergic neurons is the thalamus (Huerta-Ocampo and others 2020; Figure 4B). Optogenetic stimulation of the ascending projections of PPN ChAT⁺ neurons to either the mediodorsal thalamic nucleus or the parafascicular thalamus nucleus did not modify the distance traveled or the locomotor speed in an open field (Ruan and others 2022). This ascending PPN ChAT⁺ inputs to thalamus likely play a role in nonlocomotor aspects such as control of sleep or arousal (Gut and Mena-Segovia 2019; Mena-Segovia and Bolam 2017; Ni and others 2016) or in cognitive flexibility such as reversal learning (Ruan and others 2022).

Stimulation in a PD Model

Chemogenetic stimulation of PPN ChAT⁺ neurons improved locomotor performance in a rat model of PD based on injection in SNc of the proteasomal inhibitor lastacystin, which resulted in a 48% loss of dopaminergic SNc neurons and 61% loss of PPN cholinergic neurons (Pienaar, Gartside, and others 2015; Pienaar, Harrison, and others 2015). Chemogenetic activation of PPN ChAT⁺ neurons increased the latency to fall on the accelerating rotarod, the stepping distance, and the number of locomotor bouts in an open field in rats (Sharma and others 2020). These effects could involve striatal circuits, since such stimulation increases in striatal interneurons the expression of c-fos, a marker of cell activation (Sharma and others 2020). The prolocomotor effect is also consistent with the observation that loss of cholinergic PPN neurons correlated with locomotor deficits in patients with PD (Karachi and others 2010). The prolocomotor effect could involve a descending cholinergic drive from PPN to reticulospinal neurons as shown in lamprey, in which the cholinergic component of the MLR was found to send direct excitation to reticulospinal neurons through nicotinic receptors (Le Ray and others 2003) and indirect descending excitation to reticulospinal neurons through a group of muscarinoceptive cells that in turn send excitation to reticulospinal cells (Smetana and others 2010). However, the prolocomotor effect evoked by chemogenetic activation of PPN cholinergic neurons in a rat model of PD (Sharma and others 2020) is in contrast with the modest or inhibitory effect on locomotion evoked by optogenetic or chemogenetic stimulation of PPN cholinergic neurons in intact rodents (Caggiano and others 2018; Josset and others 2018; Roseberry and others 2016). Whether PPN cholinergic neurons acquire a stronger modulatory role on locomotor output in PD conditions is not known. In patients with PD, cholinesterase inhibitors do not strongly improve locomotor function, although the interpretation relative to the PPN is limited since several regions are affected by such pharmacologic intervention (Mancini and others 2019).

Altogether, a subset of PPN ChAT⁺ neurons appears to be a relevant target in PD conditions to improve locomotor function. To identify the subtype of interest, future studies should determine whether different PPN cholinergic neurons control different aspects of locomotion through different brain targets (Figure 4B).

Implications for Disease and Future Directions

The recent studies strengthened the idea that the MLR is a multifunctional brain region (Ryczko and Dubuc 2013) that comprises cell types with opposing effects on motor output (Arber and Costa 2022; for recent review, Ferreira-Pinto and others 2018; Leiras and others 2022). The best cell type to target in the MLR to improve locomotor function in PD is just starting to be studied in animal research. Most clinical studies have targeted the PPN, leaving the CnF largely unexplored (Chang and others 2020; Goetz and others 2019). The CnF is starting to be considered in some clinical studies aiming at reducing freezing of gait in PD. A nontrivial task for neurosurgeons is to differentiate between CnF and PPN when positioning DBS electrodes. To improve the precision of stereotaxic targeting, a team defined a Brainstem Normalized Coordinate System in relation to the pontomesencephalic junction and found that good DBS responders had their electrodes in a site that encompassed the posterior PPN and CnF (Goetz and others 2019). A prospective pilot trial from another team revealed encouraging results when targeting the CnF in a patient with PD and levodopa-resistant freezing of gait (improved “timed up and go” test, increased stride length and velocity, longer swing phase duration; Chang, Cajigas, and others 2021). Nevertheless, selectively targeting the CnF may not be sufficient to drastically change the behavioral outcome, because CnF glutamatergic and GABAergic cells are intermingled. A clinical study in which CnF DBS was performed in 5 patients reported increased swing phase duration and shorter anticipatory adjustments but no improvement in the clinical scores (Bourilhon and others 2022).

Stimulation interventions with more specific targeting are needed to improve their efficiency in PD. In animals, so far, the best cell types to activate to promote locomotion are CnF glutamatergic neurons (Fougère and others 2021), some glutamatergic neurons in the caudal PPN (Masini and Kiehn 2022), and some cholinergic PPN neurons (Pienaar, Gartside, and others 2015; Sharma and others 2020; Figure 2). The cells to avoid activating are the GABAergic neurons in the CnF (Caggiano and others 2018) and PPN, which stop locomotion (Caggiano and others 2018) or evoke slow segmented locomotion with abnormal limb movements (Masini and Kiehn 2022; Figures 2 and 6). Concerning PPN glutamatergic, cholinergic, and GABAergic neurons, further studies should differentiate those promoting locomotion from those stopping locomotion, although for PPN glutamatergic neurons, the caudal ones appear to be the best candidates to promote locomotion (Masini and Kiehn 2022). Another parameter to consider is the degeneration status of the target neurons. Cholinergic PPN neurons degenerate in PD (Sébille and others 2019), but whether CnF and PPN glutamatergic neurons degenerate in PD needs to be examined, since some noncholinergic neurons are lost in the MLR in PD (Sébille and others 2019).

Some of the controversies observed during manipulation or recording of MLR cell populations may also be related, at least in part, to differences in the behavioral approaches used to record locomotor activity. Head-fixed mice placed on a trackball can run continuously during 10 to 20 s (Roseberry and others 2016). On a treadmill, mice are made to walk during 30 to 50 s (Caggiano and others 2018). In contrast, in mice moving freely in an open field, the duration of a locomotor bout is ~1 s (Fougère and others 2021). Different network dynamics may be recruited in these substantially different locomotor behaviors. Moreover, some MLR cells may control movement in a context-dependent manner (Caggiano and others 2018; Gut and others 2022; Kim and others 2017). Such dependency was exemplified for dorsal raphe serotoninergic neurons: in the same mice, their optogenetic activation stopped locomotion in an open field but did not impair rotarod performance and did not stop locomotion in a linear corridor exposed to a bright light with water rewards at each end (Correia and others 2017).

Beyond PD, the MLR is considered a potential target in spinal cord injury (Bachmann and others 2013; Bonizzato and others 2021; Chari and others 2017; Hofer and others 2022; Richardson 2014; Stieglitz and others 2021), supranuclear palsy (Scelzo and others 2017; Leimbach and others 2019), primary progressive freezing of gait (Ostrem and others 2010; Wilcox and others 2011), and stroke (Fluri and others 2017). Selective activation of CnF glutamatergic neurons was recently shown to improve functional outcome in chronic spinal cord injury in mice (Roussel and others 2022). Better targeting of the cell types of interest should ideally be achieved in the future by using optimized DBS protocols, pharmacotherapy, or the development of optogenetics for human use (Ratner and others 2021). Optogenetic therapy is increasingly considered to improve visual function for diseases involving photoreceptor degeneration such as retinis pigmentosa. In nonhuman primates, retinal ganglion cells can be made to express ChrimsonR, an excitatory opsin sensitive to ~590-nm yellow light following adeno-associated virus injection in the retina (Gauvain and others 2021). The stable expression of this opsin allows reliable light-evoked spiking activity in retinal ganglion cells (Gauvain and others 2021). A first patient with retinis pigmentosa showed partial functional recovery after optogenetic therapy (Sahel and others 2021). Currently at least four clinical trials based on optogenetics aim to improve the visual function in patients with such neurodegenerative disease (De Silva and Moore 2022). This first breakthrough may lay the foundation for the future use of optogenetics to improve locomotor function in patients with PD, spinal cord injury, or other locomotor deficits.

Footnotes

Acknowledgements

I thank the GENSAT project for having kindly provided a photograph of a Nissl staining of the mouse brain. I thank Pr. Kiehn who kindly accepted to let me illustrate the work of his team in Figure 6.

Declaration of Conflicting Interests

The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Natural Sciences and Engineering Research Council of Canada (RGPIN-2017-05522 and RTI-2019-00628), the Canadian Institutes of Health Research (407083), the Fonds de la Recherche du Québec–Santé (Junior 1 awards 34920 and 36772 and Junior 2 award 297238), the Canada Foundation for Innovation (39344), the Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (start-up funding and PAFI grant), the Faculté de médecine et des sciences de la santé (start-up funding), the Centre d’excellence en Neurosciences de l’Université de Sherbrooke, and the fonds Jean-Luc Mongrain de la fondation du CHUS. This study has received funding from the European Research Council under the European Union’s Horizon 2020 research and innovation program (951477).

ORCID iD

Dimitri Ryczko

References

Arber

Costa

. 2022. Networking brainstem and basal ganglia circuits for movement. Nat Rev Neurosci 23:342–60.

Assous

Dautan

Tepper

Mena-Segovia

. 2019. Pedunculopontine glutamatergic neurons provide a novel source of feedforward inhibition in the striatum by selectively targeting interneurons. J Neurosci 39:4727–37.

Bachmann

Matis

Lindau

Felder

Gullo

Schwab

. 2013. Deep brain stimulation of the midbrain locomotor region improves paretic hindlimb function after spinal cord injury in rats. Sci Transl Med 5:208ra146.

Baksa

Kovács

Bayasgalan

Szentesi

Kőszeghy

Szücs

, and others. 2019. Characterization of functional subgroups among genetically identified cholinergic neurons in the pedunculopontine nucleus. Cell Mol Life Sci 76:2799–815.

Bernau

Puzdrowski

Leonard

. 1991. Identification of the midbrain locomotor region and its relation to descending locomotor pathways in the Atlantic stingray, Dasyatis sabina. Brain Res 557:83–94.

Bonizzato

James

Pidpruzhnykova

Pavlova

Shkorbatova

Baud

, and others. 2021. Multi-pronged neuromodulation intervention engages the residual motor circuitry to facilitate walking in a rat model of spinal cord injury. Nat Commun 12:1925.

Bourilhon

Mullie

Olivier

Cherif

Belaid

Grabli

, and others. 2022. Stimulation of the pedunculopontine and cuneiform nuclei for freezing of gait and falls in Parkinson disease: cross-over single-blinded study and long-term follow-up. Parkinsonism Relat Disord 96:13–17.

Bouvier

Caggiano

Leiras

Caldeira

Bellardita

Balueva

, and others. 2015. Descending command neurons in the brainstem that halt locomotion. Cell 163:1191–203.

Bretzner

Brownstone

. 2013. Lhx3-Chx10 reticulospinal neurons in locomotor circuits. J Neurosci 33:14681–92.

10.

Brimblecombe

Threlfell

Dautan

Kosillo

Mena-Segovia

Cragg

. 2018. Targeted activation of cholinergic interneurons accounts for the modulation of dopamine by striatal nicotinic receptors. eNeuro 5. https://www.eneuro.org/content/5/5/ENEURO.0397-17.2018

11.

Brocard

Dubuc

. 2003. Differential contribution of reticulospinal cells to the control of locomotion induced by the mesencephalic locomotor region. J Neurophysiol 90:1714–27.

12.

Brocard

Ryczko

Fénelon

Hatem

Gonzales

Auclair

, and others. 2010. The transformation of a unilateral locomotor command into a symmetrical bilateral activation in the brainstem. J Neurosci 30:523–33.

13.

Buchanan

Grillner

. 1987. Newly identified “glutamate interneurons” and their role in locomotion in the lamprey spinal cord. Science 236:312–4.

14.

Cabelguen

J-M

Bourcier-Lucas

Dubuc

. 2003. Bimodal locomotion elicited by electrical stimulation of the midbrain in the salamander Notophthalmus viridescens. J Neurosci 23:2434–9.

15.

Caggiano

Leiras

Goñi-Erro

Masini

Bellardita

Bouvier

, and others. 2018. Midbrain circuits that set locomotor speed and gait selection. Nature 553:455–60.

16.

Capelli

Pivetta

Soledad Esposito

Arber

. 2017. Locomotor speed control circuits in the caudal brainstem. Nature 551:373–7.

17.

Carbo-Tano

Lapoix

Jia

Auclair

Dubuc

Wyart

. 2022. Functional coupling of the mesencephalic locomotor region and V2a reticulospinal neurons driving forward locomotion. Preprint available from https://www.biorxiv.org/content/10.1101/2022.04.01.486703v1

18.

Carvalho

Tanke

Kropff

Witter

Moser

M-B

Moser

. 2020. A brainstem locomotor circuit drives the activity of speed cells in the medial entorhinal cortex. Cell Rep 32:108123.

19.

Chambers

Coyle

Sergio

Lanza

Saito

Topping

, and others. 2021. Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats. Euro J Neurosci 53:2835–47.

20.

Chang

Cajigas

Guest

Noga

Widerström-Noga

Haq

, and others. 2021. MR tractography-based targeting and physiological identification of the cuneiform nucleus for directional DBS in a Parkinson’s disease patient with levodopa-resistant freezing of gait. Front Hum Neurosci 15:676755.

21.

Chang

Cajigas

Opris

Guest

Noga

. 2020. Dissecting brainstem locomotor circuits: converging evidence for cuneiform nucleus stimulation. Front Syst Neurosci 14:64.

22.

Chang

Santamaria

Sanchez

Villamil

Saraiva

Benavides

, and others. 2021. Deep brain stimulation of midbrain locomotor circuits in the freely moving pig. Brain Stimul 14:467–76.

23.

Chari

Hentall

Papadopoulos

Pereira

EAC

. 2017. Surgical neurostimulation for spinal cord injury. Brain Sci 7:E18.

24.

Correia

Lottem

Banerjee

Machado

Carey

Mainen

. 2017. Transient inhibition and long-term facilitation of locomotion by phasic optogenetic activation of serotonin neurons. Elife 6:e20975.

25.

Cregg

Leiras

Montalant

Wanken

Wickersham

Kiehn

. 2020. Brainstem neurons that command mammalian locomotor asymmetries. Nat Neurosci 23:730–40.

26.

da Silva

Tecuapetla

Paixão

Costa

. 2018. Dopamine neuron activity before action initiation gates and invigorates future movements. Nature 554:244–8.

27.

Dautan

Huerta-Ocampo

Gut

Valencia

Kondabolu

Kim

, and others. 2020. Cholinergic midbrain afferents modulate striatal circuits and shape encoding of action strategies. Nat Commun 11:1739.

28.

Dautan

Huerta-Ocampo

Witten

Deisseroth

Bolam

Gerdjikov

, and others. 2014. A major external source of cholinergic innervation of the striatum and nucleus accumbens originates in the brainstem. J Neurosci 34:4509–18.

29.

Dautan

Kovács

Bayasgalan

Diaz-Acevedo

Pal

Mena-Segovia

. 2021. Modulation of motor behavior by the mesencephalic locomotor region. Cell Rep 36:109594.

30.

Dautan

Souza

Huerta-Ocampo

Valencia

Assous

Witten

, and others. 2016. Segregated cholinergic transmission modulates dopamine neurons integrated in distinct functional circuits. Nat Neurosci 19:1025–33.

31.

Demain

Westby

GWM

Fernandez-Vidal

Karachi

Bonneville

, and others. 2014. High-level gait and balance disorders in the elderly: a midbrain disease? J Neurol 261:196–206.

32.

De Silva

Moore

. 2022. Optogenetic approaches to therapy for inherited retinal degenerations. J Physiol 600: 4623–32.

33.

Duty

Jenner

. 2011. Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164:1357–91.

34.

Eidelberg

Walden

Nguyen

. 1981. Locomotor control in macaque monkeys. Brain 104:647–63.

35.

Ferreira-Pinto

Kanodia

Falasconi

Sigrist

Esposito

Arber

. 2021. Functional diversity for body actions in the mesencephalic locomotor region. Cell 184:4564–78.e18.

36.

Ferreira-Pinto

Ruder

Capelli

Arber

. 2018. Connecting circuits for supraspinal control of locomotion. Neuron 100:361–74.

37.

Fluri

Malzahn

Homola

Schuhmann

Kleinschnitz

Volkmann

. 2017. Stimulation of the mesencephalic locomotor region for gait recovery after stroke. Ann Neurol 82:828–40.

38.

Fougère

Flaive

Frigon

Ryczko

. 2019. Descending dopaminergic control of brainstem locomotor circuits. Curr Opin Physiol 8:30–5.

39.

Fougère

van der Zouwen

Boutin

Neszvecsko

Sarret

Ryczko

. 2021. Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus controls locomotion in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A 118:e2110934118.

40.

Galtieri

Estep

Wokosin

Traynelis

Surmeier

. 2017. Pedunculopontine glutamatergic neurons control spike patterning in substantia nigra dopaminergic neurons. Elife 6:e30352.

41.

Garcia-Rill

Houser

Skinner

Smith

Woodward

. 1987. Locomotion-inducing sites in the vicinity of the pedunculopontine nucleus. Brain Res Bull 18:731–8.

42.

Garcia-Rill

Saper

Rye

Kofler

Nonnekes

Lozano

, and others. 2019. Focus on the pedunculopontine nucleus: consensus review from the May 2018 Brainstem Society meeting in Washington, DC, USA. Clin Neurophysiol 130:925–40.

43.

Gariépy

J-F

Missaghi

Chevallier

Chartré

Robert

Auclair

, and others. 2012. Specific neural substrate linking respiration to locomotion. Proc Natl Acad Sci U S A 109:E84–92.

44.

Gauvain

Akolkar

Chaffiol

Arcizet

Khoei

Desrosiers

, and others. 2021. Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates. Commun Biol 4:125.

45.

Gay

Belaid

Rogers

Pérez-García

Roustan

Bardinet

, and others. 2020. Anatomo-functional mapping of the primate mesencephalic locomotor region using stereotactic lesions. Mov Disord 35:789–99.

46.

Goetz

Bhattacharjee

Ferraye

Fraix

Maineri

Nosko

, and others. 2019. Deep brain stimulation of the pedunculopontine nucleus area in Parkinson disease: MRI-based anatomoclinical correlations and optimal target. Neurosurgery 84:506–18.

47.

Goetz

Piallat

Bhattacharjee

Mathieu

David

Chabardès

. 2016. On the role of the pedunculopontine nucleus and mesencephalic reticular formation in locomotion in nonhuman primates. J Neurosci 36:4917–29.

48.

Grätsch

Auclair

Demers

Auguste

Hanna

Büschges

, and others. 2019. A brainstem neural substrate for stopping locomotion. J Neurosci 39:1044–57.

49.

Grillner

El Manira

. 2020. Current principles of motor control, with special reference to vertebrate locomotion. Physiol Rev 100:271–320.

50.

Guillaumin

Serra

Georges

Wallén-Mackenzie

. 2021. Experimental investigation into the role of the subthalamic nucleus (STN) in motor control using optogenetics in mice. Brain Res 1755:147226.

51.

Gut

Mena-Segovia

. 2019. Dichotomy between motor and cognitive functions of midbrain cholinergic neurons. Neurobiol Dis 128:59–66.

52.

Gut

Winn

. 2015. Deep brain stimulation of different pedunculopontine targets in a novel rodent model of parkinsonism. J Neurosci 35:4792–803.

53.

Gut

Yilmaz

Kondabolu

Huerta-Ocampo

Mena-Segovia

. 2022. Selective inhibition of goal-directed actions in the mesencephalic locomotor region. Preprint available from https://www.biorxiv.org/content/10.1101/2022.01.18.476772v1

54.

Hérent

Diem

Fortin

Bouvier

. 2021. Upregulation of breathing rate during running exercise by central locomotor circuits. Preprint available from https://www.biorxiv.org/content/10.1101/2021.07.28.453983v1

55.

Hofer

A-S

Scheuber

Sartori

Good

Stalder

Hammer

, and others. 2022. Stimulation of the cuneiform nucleus enables training and boosts recovery after spinal cord injury. Brain 145:3681–97.

56.

Howe

Dombeck

. 2016. Rapid signalling in distinct dopaminergic axons during locomotion and reward. Nature 535:505–10.

57.

Huerta-Ocampo

Hacioglu-Bay

Dautan

Mena-Segovia

. 2020. Distribution of midbrain cholinergic axons in the thalamus. eNeuro 7:ENEURO.0454-19.2019.

58.

Josset

Roussel

Lemieux

Lafrance-Zoubga

Rastqar

Bretzner

. 2018. Distinct contributions of mesencephalic locomotor region nuclei to locomotor control in the freely behaving mouse. Curr Biol 28:884–901.e3.

59.

Juvin

Grätsch

Trillaud-Doppia

Gariépy

J-F

Büschges

Dubuc

. 2016. A specific population of reticulospinal neurons controls the termination of locomotion. Cell Rep 15:2377–86.

60.

Karachi

Grabli

Bernard

Tandé

Wattiez

Belaid

, and others. 2010. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 120:2745–54.

61.

Kim

Adhikari

Deisseroth

. 2017. Integration of optogenetics with complementary methodologies in systems neuroscience. Nat Rev Neurosci 18:222–35.

62.

Klug

Engelhardt

Cadman

Smith

Ayala

, and others. 2018. Differential inputs to striatal cholinergic and parvalbumin interneurons imply functional distinctions. eLife 7:e35657.

63.

Korte

Jaarsma

Luiten

Bohus

. 1992. Mesencephalic cuneiform nucleus and its ascending and descending projections serve stress-related cardiovascular responses in the rat. J Auton Nerv Syst 41:157–76.

64.

Kreeger

Connelly

Mehta

Zemelman

Golding

. 2021. Excitatory cholecystokinin neurons of the midbrain integrate diverse temporal responses and drive auditory thalamic subdomains. Proc Natl Acad Sci U S A 118:e2007724118.

65.

Kroeger

Ferrari

Petit

Mahoney

Fuller

Arrigoni

, and others. 2017. Cholinergic, glutamatergic, and GABAergic neurons of the pedunculopontine tegmental nucleus have distinct effects on sleep/wake behavior in mice. J Neurosci 37:1352–66.

66.

Kuo

S-H

Kenney

Jankovic

. 2008. Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Disord 23:616–9.

67.

Lee

Hoy

Bonci

Wilbrecht

Stryker

Niell

. 2014. Identification of a brainstem circuit regulating visual cortical state in parallel with locomotion. Neuron 83:455–66.

68.

Leimbach

Gratwicke

Foltynie

Limousin

Zrinzo

Jahanshahi

. 2019. The effects of deep brain stimulation of the pedunculopontine nucleus on cognition in Parkinson’s disease and progressive supranuclear palsy. Clin Park Relat Disord 1:48–51.

69.

Leiras

Cregg

Kiehn

. 2022. Brainstem circuits for locomotion. Annu Rev Neurosci 45:63–85.

70.

Lemieux

Bretzner

. 2019. Glutamatergic neurons of the gigantocellular reticular nucleus shape locomotor pattern and rhythm in the freely behaving mouse. PLoS Biol 17:e2003880.

71.

Le Ray

Brocard

Bourcier-Lucas

Auclair

Lafaille

Dubuc

. 2003. Nicotinic activation of reticulospinal cells involved in the control of swimming in lampreys. Eur J Neurosci 17:137–48.

72.

MacLaren

DAA

Santini

Russell

Markovic

Clark

. 2014. Deficits in motor performance after pedunculopontine lesions in rats—impairment depends on demands of task. Eur J Neurosci 40:3224–36.

73.

Mancini

Chung

Zajack

Martini

Ramsey

Lapidus

, and others. 2019. Effects of augmenting cholinergic neurotransmission on balance in Parkinson’s disease. Parkinsonism Relat Disord 69:40–7.

74.

Martinez-Gonzalez

Bolam

Mena-Segovia

. 2011. Topographical organization of the pedunculopontine nucleus. Front Neuroanat 5:22.

75.

Masdeu

Alampur

Cavaliere

Tavoulareas

. 1994. Astasia and gait failure with damage of the pontomesencephalic locomotor region. Ann Neurol 35:619–21.

76.

Masini

Kiehn

. 2022. Targeted activation of midbrain neurons restores locomotor function in mouse models of parkinsonism. Nat Commun 13:504.

77.

Mazzone

Lozano

Stanzione

Galati

Scarnati

Peppe

, and others. 2005. Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson’s disease. Neuroreport 16:1877–81.

78.

Mena-Segovia

Bolam

. 2017. Rethinking the pedunculopontine nucleus: from cellular organization to function. Neuron 94:7–18.

79.

Mena-Segovia

Sims

Magill

Bolam

. 2008. Cholinergic brainstem neurons modulate cortical gamma activity during slow oscillations. J Physiol 586:2947–60.

80.

Meng

Wang

L-J

Chen

Chao

, and others. 2016. Manipulations of MeCP2 in glutamatergic neurons highlight their contributions to Rett and other neurological disorders. Elife 5:e14199.

81.

Musienko

Zelenin

Lyalka

Orlovsky

Deliagina

. 2008. Postural performance in decerebrated rabbit. Behav Brain Res 190:124–34.

82.

Netzer

Sevoz-Couche

. 2021. Rostral cuneiform nucleus and the defence reaction: direct and indirect midbrain-medullary 5-HT mechanisms in baroreflex inhibition. Br J Pharmacol 178:1819–35.

83.

K-M

Hou

X-J

Yang

C-H

Dong

Zhang

, and others. 2016. Selectively driving cholinergic fibers optically in the thalamic reticular nucleus promotes sleep. Elife 5:e10382.

84.

Noga

Guest

. 2021. Combined neuromodulatory approaches in the central nervous system for treatment of spinal cord injury. Curr Opin Neurol 34:804–11.

85.

Noga

Whelan

. 2022. The mesencephalic locomotor region: beyond locomotor control. Front Neural Circuits 16:884785.

86.

Norton

ABW

Clark

Taylor

Mizumori

SJY

. 2011. Independent neural coding of reward and movement by pedunculopontine tegmental nucleus neurons in freely navigating rats. Eur J Neurosci 33:1885–96.

87.

Opris

Dai

Johnson

DMG

Sanchez

Villamil

Xie

, and others. 2019. Activation of brainstem neurons during mesencephalic locomotor region-evoked locomotion in the cat. Front Syst Neurosci 13:69.

88.

Ostrem

Christine

Glass

Schrock

Starr

. 2010. Pedunculopontine nucleus deep brain stimulation in a patient with primary progressive freezing gait disorder. Stereotact Funct Neurosurg 88:51–5.

89.

Pernia-Andrade

Wenger

Esposito

Tovote

. 2021. Circuits for state-dependent modulation of locomotion. Front Hum Neurosci 15:745689.

90.

Petzold

Valencia

Pál

Mena-Segovia

. 2015. Decoding brain state transitions in the pedunculopontine nucleus: cooperative phasic and tonic mechanisms. Front Neural Circuits 9:68.

91.

Pienaar

Gartside

Sharma

De Paola

Gretenkord

Withers

, and others. 2015. Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson’s disease. Mol Neurodegener 10:47.

92.

Pienaar

Harrison

Elson

Bury

Woll

Simon

, and others. 2015. An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson’s disease. Brain Struct Funct 220:479–500.

93.

Plaha

Gill

. 2005. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson’s disease. Neuroreport 16:1883–7.

94.

Ratner

. 2021. Light-activated genetic therapy to treat blindness enters clinic. Nat Biotechnol 39:126–7.

95.

Richardson

. 2014. Deep brain stimulation for locomotor recovery following spinal cord injury. Neurosurgery 74: N18–9.

96.

Roseberry

Lee

Lalive

Wilbrecht

Bonci

Kreitzer

. 2016. Cell-type-specific control of brainstem locomotor circuits by basal ganglia. Cell 164:526–37.

97.

Roussel

Lafrance-Zoubga

Josset

Lemieux

Bretzner

. 2022. Functional contribution of mesencephalic locomotor region nuclei to locomotor recovery after spinal cord injury. Preprint available from https://www.biorxiv.org/content/10.1101/2022.08.22.504420v1

98.

Roth

. 2016. DREADDs for neuroscientists. Neuron 89:683–94.

99.

Ruan

K-Y

Zheng

Yan

Y-Q

Wang

Z-X

Chen

, and others. 2022. Cholinergic neurons in the pedunculopontine nucleus guide reversal learning by signaling the changing reward contingency. Cell Rep 38:110437.

100.

Ryczko

Auclair

Cabelguen

J-M

Dubuc

. 2016. The mesencephalic locomotor region sends a bilateral glutamatergic drive to hindbrain reticulospinal neurons in a tetrapod. J Comp Neurol 524:1361–83.

101.

Ryczko

Cone

Alpert

Goetz

Auclair

Dubé

, and others. 2016. A descending dopamine pathway conserved from basal vertebrates to mammals. Proc Natl Acad Sci U S A 113:E2440–9.

102.

Ryczko

Dubuc

. 2013. The multifunctional mesencephalic locomotor region. Curr Pharm Des 19:4448–70.

103.

Ryczko

Dubuc

. 2017. Dopamine and the brainstem locomotor networks: from lamprey to human. Front Neurosci 11:295.

104.

Ryczko

Grätsch

Alpert

Cone

Kasemir

Ruthe

, and others. 2020. Descending dopaminergic inputs to reticulospinal neurons promote locomotor movements. J Neurosci 40:8478–90.

105.

Sahel

J-A

Boulanger-Scemama

Pagot

Arleo

Galluppi

Martel

, and others. 2021. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med 27:1223–9.

106.

Scelzo

Lozano

Hamani

Poon

Y-Y

Aldakheel

Zadikoff

, and others. 2017. Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. J Neurol Neurosurg Psychiatry 88:613–6.

107.

Schweizer

Pupe

Arvidsson

Nordenankar

Smith-Anttila

CJA

Mahmoudi

, and others. 2014. Limiting glutamate transmission in a Vglut2-expressing subpopulation of the subthalamic nucleus is sufficient to cause hyperlocomotion. Proc Natl Acad Sci U S A 111:7837–42.

108.

Sébille

Rolland

A-S

Faillot

Perez-Garcia

Colomb-Clerc

Lau

, and others. 2019. Normal and pathological neuronal distribution of the human mesencephalic locomotor region. Mov Disord 34:218–27.

109.

Sharma

Wells

Rizzo

Elson

Passchier

Rabiner

, and others. 2020. DREADD activation of pedunculopontine cholinergic neurons reverses motor deficits and restores striatal dopamine signaling in parkinsonian rats. Neurotherapeutics 17:1120–41.

110.

Shik

Severin

Orlovskiĭ

. 1966. Control of walking and running by means of electric stimulation of the midbrain. Article in Russian. Biofizika 11:659–66.

111.

Shine

Matar

Ward

Bolitho

Gilat

Pearson

, and others. 2013. Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinson’s disease. Brain 136:1204–15.

112.

Sirota

Di Prisco

Dubuc

. 2000. Stimulation of the mesencephalic locomotor region elicits controlled swimming in semi-intact lampreys. Eur J Neurosci 12: 4081–92.

113.

Smetana

Juvin

Dubuc

Alford

. 2010. A parallel cholinergic brainstem pathway for enhancing locomotor drive. Nat Neurosci 13:731–8.

114.

Steeves

Sholomenko

Webster

. 1987. Stimulation of the pontomedullary reticular formation initiates locomotion in decerebrate birds. Brain Res 401:205–12.

115.

Stieglitz

Hofer

A-S

Bolliger

Oertel

Filli

Willi

, and others. 2021. Deep brain stimulation for locomotion in incomplete human spinal cord injury (DBS-SCI): protocol of a prospective one-armed multi-centre study. BMJ Open 11:e047670.

116.

Thevathasan

Debu

Aziz

Bloem

Blahak

Butson

, and others;, and Movement Disorders Society PPN DBS Working Group in collaboration with the World Society for Stereotactic and Functional Neurosurgery. 2018. Pedunculopontine nucleus deep brain stimulation in Parkinson’s disease: a clinical review. Mov Disord 33:10–20.

117.

Thevathasan

Pogosyan

Hyam

Jenkinson

Foltynie

Limousin

, and others. 2012. Alpha oscillations in the pedunculopontine nucleus correlate with gait performance in parkinsonism. Brain 135:148–60.

118.

Usseglio

Gatier

Heuzé

Hérent

Bouvier

. 2020. Control of orienting movements and locomotion by projection-defined subsets of brainstem V2a neurons. Curr Biol 30:4665–81.e6.

119.

van der Zouwen

Boutin

Fougère

Flaive

Vivancos

Santuz

, and others. 2021. Freely behaving mice can brake and turn during optogenetic stimulation of the mesencephalic locomotor region. Front Neural Circuits 15:639900.

120.

Xiao

Cho

Zhou

Treweek

Chan

McKinney

, and others. 2016. Cholinergic mesopontine signals govern locomotion and reward through dissociable midbrain pathways. Neuron 90:333–47.

121.

Xiao

Cai

Zhou

Wen

, and others. 2017. Selective cholinergic depletion of pedunculopontine tegmental nucleus aggravates freezing of gait in parkinsonian rats. Neurosci Lett 659:92–8.

122.

Wang

Zhang

Szábo

Sun

Q-Q

. 2013. Distribution of CaMKIIα expression in the brain in vivo, studied by CaMKIIα-GFP mice. Brain Res 1518:9–25.

123.

Wilcox

Cole

Wong

Coyne

Silburn

Kerr

. 2011. Pedunculopontine nucleus deep brain stimulation produces sustained improvement in primary progressive freezing of gait. J Neurol Neurosurg Psychiatry 82:1256–9.

124.

Yoo

Zell

Punta

Ramajayam

Shen

, and others. 2017. Activation of pedunculopontine glutamate neurons is reinforcing. J Neurosci 37:38–46.

The Mesencephalic Locomotor Region: Multiple Cell Types,Multiple Behavioral Roles,and Multiple Implications for Disease

Abstract

Keywords

Selectivity and time scales of Electrical Stimulation versus Optogenetic or Chemogenetic Stimulation.

Targeting the MLR at Large by Using Molecular Tools: The First Studies

CnF Vglut2+ Neurons: Slow and Fast Gaits

Stimulation

Inhibition

Activity during Behavior

Cell Properties

Target-Specific Effects

Stimulation in a PD Model

CnF VGAT Neurons: Locomotor Arrests

PPN Vglut2+ Neurons: Slow Gaits, Posture Adjustments, and Locomotor Arrests

Stimulation

Inhibition

Activity during Behavior

Cell Properties

Target-Specific Effects

Stimulation in a PD Model

PPN GABAergic Neurons: Locomotor Arrests and Slow Segmented Locomotion

Stimulation

Target-Specific Effects

Stimulation in a PD Model

PPN Cholinergic Neurons: A Complex Role

Stimulation

Inhibition

Lesion

Activity during Behavior

Cell Properties

Target-Specific Effects

Stimulation in a PD Model

Implications for Disease and Future Directions

Footnotes

Acknowledgements

Declaration of Conflicting Interests

Funding

ORCID iD

References

CnF Vglut2⁺ Neurons: Slow and Fast Gaits

PPN Vglut2⁺ Neurons: Slow Gaits, Posture Adjustments, and Locomotor Arrests